Eyeworld Daily News

2022 EyeWorld Daily News Friday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/1465478

Contents of this Issue


Page 74 of 74

72 | EYEWORLD DAILY NEWS | JULY 23, 2021 Patients should have insured access to the necessary treatment for MGD, and doctors should receive fair reimbursement for that treatment. Today, we don't have this. Which is why only 5% of patients get a heat and expression treatment 1 , when 86% may need it. 2 We say that's not right for anyone. Sight Sciences and the TearCare® System are boldly stepping forward to fight for equitable care. Learn more about our vision to remove the barriers to MGD care. Come by our booth #1001 THIS IS YOUR SIGN TO FIGHT FOR EQUITABLE MGD CARE Shawn O'Neil Chief Commercial O cer © 2022 Sight Sciences, Inc. 4/22 TC-2331-US.v1 1. Market Scope 2021 Ocular Surface Disease Survey 2. Lemp, MA., et al. Cornea. 2012;31(5),472-478. Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for contraindications, warnings, precautions and adverse events.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2022 EyeWorld Daily News Friday